[HCV entry as a new therapeutic target in chronic hepatitis C].
According to WHO data the hepatitis C virus (HCV) has already infected 170 million people worldwide, and 750,000 of them in Poland what amounts some 1.4% of general country population. Currently used antiviral therapy with pegylated interferon alpha and ribavirin has only 50% effectiveness. Many new drugs and molecules, especially inhibiting viral replication, are studied in preclinical and clinical trials. However, still unknown HCV entry process can be a new, promising therapeutic target in chronic HCV infection.